 |
12 Diseases |  |
4 Trials |
|
4 Trials |  |
233 News |  |
| 1234» |
- | Trumenba (meningococcal B vaccine) / Pfizer, Bexsero (meningococcal group B vaccine) / GSK
Journal: Whole-genome sequencing of Neisseria meningitidis collected in Chile from pediatric patients during 2016-2019 and coverage vaccine prediction. (Pubmed Central) - Sep 15, 2024
genetic variability of the Chilean strains that its different from other countries, and until now limit the coverage prediction of vaccine with the available tools like gMATS and MenDeVAR.
- ||||||| Trumenba (meningococcal B vaccine) / Pfizer
Trial completion, Enrollment change: A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States. (clinicaltrials.gov) - Sep 3, 2024
P=N/A, N=1307378, Completed, Sponsor: Pfizer
genetic variability of the Chilean strains that its different from other countries, and until now limit the coverage prediction of vaccine with the available tools like gMATS and MenDeVAR. Recruiting --> Completed | N=999 --> 1307378
- MenQuadfi (meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine) / Sanofi
Phase classification: Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants (clinicaltrials.gov) - Aug 27, 2024
P1, N=576, Terminated, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Completed | N=999 --> 1307378 Phase classification: P1/2 --> P1
- |||||| MenQuadfi (meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine) / Sanofi
Trial termination: Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants (clinicaltrials.gov) - Jul 31, 2024
P1/2, N=576, Terminated, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Terminated; Sponsor decision. Termination decision not related to any safety concern.
- ||| MenQuadfi (meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine) / Sanofi
Enrollment closed: Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents (clinicaltrials.gov) - Jul 5, 2024
P1/2, N=1220, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Termination decision not related to any safety concern. Recruiting --> Active, not recruiting
- ||| MenQuadfi (meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine) / Sanofi
Trial initiation date: Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents (clinicaltrials.gov) - Jun 18, 2024
P1/2, N=1220, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Active, not recruiting Initiation date: Jan 2023 --> Oct 2023
- ||| MenQuadfi (meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine) / Sanofi
Trial initiation date: Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents (clinicaltrials.gov) - May 29, 2024
P1/2, N=1220, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Initiation date: Jan 2023 --> Oct 2023 Initiation date: Oct 2023 --> Jan 2023
- | Penbraya (PF-06886992) / Pfizer
Journal: Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ?10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. (Pubmed Central) - Apr 22, 2024
Different manufacturers' serogroup B-containing vaccines are not interchangeable; therefore, when MenACWY-TT/MenB-FHbp is used, subsequent doses of MenB should be from the same manufacturer (Pfizer Inc.). This report summarizes evidence considered for these recommendations and provides clinical guidance for the use of MenACWY-TT/MenB-FHbp.
- Penbraya (PF-06886992) / Pfizer
Phase classification: A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants (clinicaltrials.gov) - Mar 25, 2024
P2, N=326, Terminated, Sponsor: Pfizer
This report summarizes evidence considered for these recommendations and provides clinical guidance for the use of MenACWY-TT/MenB-FHbp. Phase classification: P2b --> P2
- | Penbraya (PF-06886992) / Pfizer
Journal: Penbraya: A pentavalent meningococcal vaccine. (Pubmed Central) - Mar 15, 2024
Phase classification: P2b --> P2 No abstract available
- ||||| Trumenba (meningococcal B vaccine) / Pfizer
Enrollment change, Trial completion date, Trial primary completion date: A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States. (clinicaltrials.gov) - Mar 2, 2024
P=N/A, N=999, Recruiting, Sponsor: Pfizer
No abstract available N=520392 --> 999 | Trial completion date: Jun 2023 --> Mar 2024 | Trial primary completion date: Jun 2023 --> Mar 2024
- | Trumenba (meningococcal B vaccine) / Pfizer
Preclinical, Journal, Predictive model: A Predictive Model of Vaccine Reactogenicity Using Data from an In (Pubmed Central) - Feb 22, 2024
A forward-validation study was performed with a vaccine not used in model development, Trumenba (meningococcal group B vaccine)...Models predicting specific AEs were less accurate. Our study presents a useful framework for the further development of vaccine reactogenicity predictive models.
- ||||| MenQuadfi (meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine) / Sanofi
New P1/2 trial: Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents (EUDRACT) - Dec 21, 2023
P1/2, N=1120, , Sponsor: Sanofi Pasteur Inc.
- ||||| MenQuadfi (meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine) / Sanofi
New P1/2 trial: Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents (clinicaltrials.gov) - Nov 13, 2023
P1/2, N=1120, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- ||| MenQuadfi (meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine) / Sanofi
Enrollment closed, Enrollment change: Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants (clinicaltrials.gov) - Sep 30, 2023
P1/2, N=576, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Our study presents a useful framework for the further development of vaccine reactogenicity predictive models. Recruiting --> Active, not recruiting | N=1800 --> 576
- ||| Trumenba (meningococcal B vaccine) / Pfizer
Trial completion: Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ?10 Years of Age (clinicaltrials.gov) - Sep 21, 2023
P4, N=53, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting | N=1800 --> 576 Active, not recruiting --> Completed
- |||||| Trumenba (meningococcal B vaccine) / Pfizer
New trial: A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States. (clinicaltrials.gov) - May 24, 2023
P=N/A, N=520392, Recruiting, Sponsor: Pfizer
- | Trumenba (meningococcal B vaccine) / Pfizer, Bexsero (meningococcal group B vaccine) / GSK
Journal: Whole genome analysis of Neisseria meningitidis isolates from invasive meningococcal disease collected in the Czech Republic over 28 years (1993-2020). (Pubmed Central) - Mar 14, 2023
For Trumenba vaccine, estimated coverage was 74.6% (for MenB) and 65.7% (for MenC, W, Y). Our results demonstrated sufficient coverage of Czech heterogeneous population of N. meningitidis with MenB vaccines and, together with surveillance data on invasive meningococcal disease in the Czech Republic, were the basis for updating recommendations for vaccination against invasive meningococcal disease.
- | Trumenba (meningococcal B vaccine) / Pfizer, Bexsero (meningococcal group B vaccine) / GSK
Journal: Characterization of invasive meningococcal disease case isolates in Atlantic Canada, 2014 to 2020: spatial-temporal variations of clones and predicted meningococcal B vaccine coverage. (Pubmed Central) - Feb 7, 2023
Meningococcal deduced vaccine antigen reactivity predicted from WGS data showed that 95.3?% of MenB were covered by Trumenba...This study provided evidence concerning the dynamics of N. meningitidis strains causing IMD in Atlantic Canada, with both geographical and temporal differences found. MenB vaccine appeared to provide good coverage of MenB IMD, especially towards the predominant strain of ST-154.
- Estimated strain coverage of serogroup B meningococcal vaccines in Russia (D / 13) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_4530;
- || MenQuadfi (meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine) / Sanofi
Trial completion date, Trial primary completion date: Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants (clinicaltrials.gov) - Jan 23, 2023
P1/2, N=1800, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
MenB vaccine appeared to provide good coverage of MenB IMD, especially towards the predominant strain of ST-154. Trial completion date: Apr 2027 --> May 2026 | Trial primary completion date: Apr 2027 --> May 2026
- |||||| Penbraya (PF-06886992) / Pfizer
Trial termination: A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants (clinicaltrials.gov) - Jan 20, 2023
P2b, N=326, Terminated, Sponsor: Pfizer
Trial completion date: Apr 2027 --> May 2026 | Trial primary completion date: Apr 2027 --> May 2026 Active, not recruiting --> Terminated; The Sponsor decided to discontinue the study based on Sponsor's careful review of available safety data in concert with the recommendation of an independent Data Monitoring Committee.
- Trumenba (meningococcal B vaccine) / Pfizer
WHOLE GENOME SEQUENCING OF INVASIVE NEISSERIA MENINGITIDIS ISOLATED IN CHILDREN IN CHILE FROM 2016 TO 2019 (Auditorium VIII) - Jan 14, 2023 - Abstract #ESPID2023ESPID_19;
For capsular genogrouping, 11 isolates contained serogroup-specific genes in cps locus, 8 were MenB and 3 were MenW. Many of the isolates were assigned to cc11 (39%), followed by cc41/44 (36.5%), and the most prevalent molecular typing were W:P1.5,2:F1-1:cc11 (33.3%) and B:P1.19,13-1:F1-18:cc41/44 (23.8%).
- || MenQuadfi (meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine) / Sanofi
Trial completion date, Trial primary completion date: Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants (clinicaltrials.gov) - Jan 5, 2023
P1/2, N=1800, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Many of the isolates were assigned to cc11 (39%), followed by cc41/44 (36.5%), and the most prevalent molecular typing were W:P1.5,2:F1-1:cc11 (33.3%) and B:P1.19,13-1:F1-18:cc41/44 (23.8%). Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
- | Trumenba (meningococcal B vaccine) / Pfizer
Journal: Genomic characterization of Japanese meningococcal strains isolated over a 17-year period between 2003 and 2020 in Japan. (Pubmed Central) - Dec 5, 2022
An in silico analysis suggested that 14.3 and 44.2% of Japanese MenB were cross-reactive with 4CMenB and rLP2086 MenB vaccines, respectively. The results in the present study revealed that some epidemiological features were unique to Japan.
- ||||||| Penbraya (PF-06886992) / Pfizer, Trumenba (meningococcal B vaccine) / Pfizer
Trial completion: A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age. (clinicaltrials.gov) - Nov 9, 2022
P3, N=1610, Completed, Sponsor: Pfizer
The results in the present study revealed that some epidemiological features were unique to Japan. Active, not recruiting --> Completed
- | Journal: Adult immunization. (Pubmed Central) - Oct 14, 2022
Active, not recruiting --> Completed No abstract available
- | Journal: Expanded table: Some vaccines for adults. (Pubmed Central) - Oct 14, 2022
No abstract available No abstract available
- |||| Trumenba (meningococcal B vaccine) / Pfizer, Bexsero (meningococcal group B vaccine) / GSK
Enrollment open: SPLEMENGO: Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia. (clinicaltrials.gov) - Oct 12, 2022
P3, N=84, Recruiting, Sponsor: Assistance Publique - H
No abstract available Not yet recruiting --> Recruiting
- Trumenba (meningococcal B vaccine) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date: Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ?10 Years of Age (clinicaltrials.gov) - Sep 29, 2022
P4, N=46, Active, not recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Aug 2023 | Trial primary completion date: Jun 2024 --> Aug 2023
- ||||||| Penbraya (PF-06886992) / Pfizer
Trial completion, Head-to-Head: MenABCWY Noninferiority Study in Healthy Participants ?10 to <26 Years of Age (clinicaltrials.gov) - Sep 13, 2022
P3, N=2407, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Aug 2023 | Trial primary completion date: Jun 2024 --> Aug 2023 Active, not recruiting --> Completed
- | Trumenba (meningococcal B vaccine) / Pfizer, Bexsero (meningococcal group B vaccine) / GSK
Journal: Demographic Features of Invasive Meningococcal Disease in Taiwan, 1993 to 2020, and Genetic Characteristics of Neisseria meningitidis Isolates, 2003 to 2020. (Pubmed Central) - Sep 10, 2022
We conducted a whole-genome sequence analysis to characterize the genetic features of the isolates and developed a cgMLST scheme for epidemiological investigation and strain tracking. The findings can be beneficial in understanding the epidemiology of IMD in Taiwan, the genetic characteristics of the bacterial strains, and the distribution of vaccine antigens for vaccine development and implementation.
- | Trumenba (meningococcal B vaccine) / Pfizer, Bexsero (meningococcal group B vaccine) / GSK
Journal: Vaccines against Neisseria meningitidis serogroup B strains - What does genomics reveal on the Portuguese strain's coverage. (Pubmed Central) - Aug 18, 2022
4CMenB and rLP2086 vaccines showed potential coverage for isolates regardless serogroup. The use of both vaccines should be considered to control possible outbreaks caused by serogroups with no vaccine available.
- || Review, Journal: Vaccination prophylaxis for recurrent invasive meningococcal diseases (Pubmed Central) - Aug 3, 2022
The risk of becoming infected again with a different or the same serotype is significantly increased after an infection has gone through and in the case of certain previous illnesses such as complement defects.The Committee for Infectious Diseases and Vaccinations of the German Academy for Pediatrics and Adolescent Health proposes the following approach for prevention of recurrent invasive meningococcal infections:Children and adolescents without a complete meningococcal vaccination status should be vaccinated with 4CMenB (Bexero®, Trumenba®) and/or vaccinated against serogroups A, C, W and Y (Menveo®, Nimenrix®, MenQuadfi®) immediately after healing of an invasive meningococcal disease according to the specification of the information for healthcare professionals. Prior isolated screening for complement deficiencies is not necessary for the vaccination decision in these patients.
- ||| Trumenba (meningococcal B vaccine) / Pfizer, Bexsero (meningococcal group B vaccine) / GSK
Trial completion date, Trial primary completion date: SPLEMENGO: Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia. (clinicaltrials.gov) - Jun 30, 2022
P3, N=84, Not yet recruiting, Sponsor: Assistance Publique - H
Prior isolated screening for complement deficiencies is not necessary for the vaccination decision in these patients. Trial completion date: Aug 2027 --> Aug 2028 | Trial primary completion date: Jul 2027 --> Jul 2028
- || Penbraya (PF-06886992) / Pfizer
Trial completion date, Trial primary completion date: A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants (clinicaltrials.gov) - Jun 30, 2022
P2b, N=326, Active, not recruiting, Sponsor: Pfizer
Trial completion date: Aug 2027 --> Aug 2028 | Trial primary completion date: Jul 2027 --> Jul 2028 Trial completion date: Jul 2023 --> Sep 2022 | Trial primary completion date: Jul 2023 --> Sep 2022
- | Trumenba (meningococcal B vaccine) / Pfizer, Bexsero (meningococcal group B vaccine) / GSK
Journal: A comparison of national vaccination policies to prevent serogroup B meningococcal disease. (Pubmed Central) - Jun 8, 2022
Our findings highlighted the significant heterogeneity in recommendations for MenB vaccination across countries. Greater transparency in reporting MenB vaccination recommendations and more robust data on implementation and the impact of vaccination would better facilitate optimizing MenB prevention strategies.
- MenQuadfi (meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine) / Sanofi
IMMUNE PERSISTENCE, IMMUNOGENICITY AND SAFETY OF A BOOSTER DOSE OF QUADRIVALENT MENINGOCOCCAL CONJUGATE VACCINE (MENACYW-TT) IN ADOLESCENTS AND ADULTS PRIMED 3 - 6 YEARS EARLIER. ([VIRTUAL]) - May 19, 2022 - Abstract #ESPID2022ESPID_1400;
At D30, the statistically planned sufficiency of hSBA seroresponse was demonstrated post MenACYW-TT booster dose regardless of the priming vaccine. D30 hSBA GMTs were comparable for serogroups A, Y and W regardless of the priming vaccine and were higher for serogroup C in MenACYW-TT primed participants.
- ||| Penbraya (PF-06886992) / Pfizer
Enrollment closed, Enrollment change: A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants (clinicaltrials.gov) - Apr 20, 2022
P2b, N=320, Active, not recruiting, Sponsor: Pfizer
D30 hSBA GMTs were comparable for serogroups A, Y and W regardless of the priming vaccine and were higher for serogroup C in MenACYW-TT primed participants. Recruiting --> Active, not recruiting | N=1325 --> 320
- ||| Trumenba (meningococcal B vaccine) / Pfizer
Journal, Adverse events: Safety profile of MenB-FHBp vaccine among adolescents: data from surveillance of Adverse Events Following Immunization in Puglia (Italy), 2018-2020. (Pubmed Central) - Apr 15, 2022
No deaths or impairment were notified in studied AEFIs. The picture of MenB-FHBp vaccine supports that the risk of AEFIs is in line with previous published data and in general acceptable.
- | Trumenba (meningococcal B vaccine) / Pfizer
Journal: Genetic characterization of clonal complex sequence type 2057 (cc2057) serogroup B Neisseria meningitidis strains unique to Japan and identification of a capsular-switched serogroup Y isolate cc2057. (Pubmed Central) - Mar 12, 2022
The potential coverage of 4CMenB and rLP2086 for cc2057 MenB strains was estimated to be very low.Conclusion. To the best of our knowledge, this is the first study to provide genetic insights from epidemiologically unique N. meningitidis cc2057 strains isolated only in Japan, an island country.
- | Trumenba (meningococcal B vaccine) / Pfizer
Journal: Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older. (Pubmed Central) - Mar 11, 2022
P1, P1/2,
Continued postmarketing safety surveillance is important for the identification of rare events. Clinicaltrials.gov: NCT01299480; NCT000808028; NCT00879814; NCT00780806; NCT01352845; NCT01352793; NCT01461993; NCT01323270; NCT01830855; NCT01461980; NCT01768117.
- ||||| Trumenba (meningococcal B vaccine) / Pfizer, Bexsero (meningococcal group B vaccine) / GSK
New P1/2 trial: Study of a novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants (EUDRACT) - Jan 27, 2022
P1/2, N=1800, , Sponsor: Sanofi Pasteur Inc.
- ||||| Penbraya (PF-06886992) / Pfizer, Trumenba (meningococcal B vaccine) / Pfizer
Enrollment closed: A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age. (clinicaltrials.gov) - Jan 19, 2022
P3, N=1614, Active, not recruiting, Sponsor: Pfizer
Clinicaltrials.gov: NCT01299480; NCT000808028; NCT00879814; NCT00780806; NCT01352845; NCT01352793; NCT01461993; NCT01323270; NCT01830855; NCT01461980; NCT01768117. Recruiting --> Active, not recruiting
- ||||| Penbraya (PF-06886992) / Pfizer
Enrollment closed, Head-to-Head: MenABCWY Noninferiority Study in Healthy Participants ?10 to <26 Years of Age (clinicaltrials.gov) - Dec 21, 2021
P3, N=2434, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Clinical, Journal: Improving meningococcal MenACWY and 4CMenB/meningococcal group B vaccine-related health literacy in patients: Importance of readability of pharmaceutical Patient Leaflets. (Pubmed Central) - Dec 16, 2021
Adoption of readability calculators and scrutiny of materials for their readability will help authors develop materials with improved understanding for vaccine recipients, potentially leading to improved health literacy and vaccine uptake. Renewed efforts should be sought to promote the information within the PIL, thereby maximizing the value of this resource with vaccine recipients, their carers and family.
- || MenQuadfi (meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine) / Sanofi
Trial completion date, Trial primary completion date: Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants (clinicaltrials.gov) - Oct 31, 2021
P1/2, N=1800, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Renewed efforts should be sought to promote the information within the PIL, thereby maximizing the value of this resource with vaccine recipients, their carers and family. Trial completion date: Apr 2025 --> Jul 2025 | Trial primary completion date: Apr 2025 --> Jul 2025
- MenQuadfi (meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccine) / Sanofi
[VIRTUAL] Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered as a Booster Dose in Adults and Adolescents Vaccinated Against Meningococcal Disease 3 - 6 Years Earlier () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_903;
P3
MenACYW-TT used as priming vaccine was able to demonstrate persistence of immune response 3-6 years later. MenACYW-TT elicits robust booster responses in adults and adolescents primed with MenACYW-TT or MCV4-CRM
- Trumenba (meningococcal B vaccine) / Pfizer, Bexsero (meningococcal group B vaccine) / GSK
[VIRTUAL] Serum Bactericidal Activity Against Circulating and Reference Strains of Meningococcal Serogroup B in the United States: A Review of Meningococcal Serogroup B (MenB) Vaccines in Adolescents and Young Adults () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_901;
MenB-FHbp and MenB-4C protect against various serogroup B strains. As for the breadth of coverage provided by these vaccines, available data show that MenB-FHbp elicits robust immune responses to a wide variety of disease-causing strains prevalent in the US ( ).
- Trumenba (meningococcal B vaccine) / Pfizer
Enrollment open: Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ?10 Years of Age (clinicaltrials.gov) - Sep 27, 2021
P4, N=50, Recruiting, Sponsor: Pfizer
As for the breadth of coverage provided by these vaccines, available data show that MenB-FHbp elicits robust immune responses to a wide variety of disease-causing strains prevalent in the US ( ). Not yet recruiting --> Recruiting